1-3 of 3
Michael Jenner, MD, PhD
Close
Sort by
Journal Articles

Early Detection of Minimal Residual Disease in Biological Prognostic Risk Groups in Chronic Lymphocytic Leukaemia (CLL) Utilizing the Novel CD160FCA Assay

Timothy W Farren, Fengting Liu, Marion Macey, Michael Jenner, MD, PhD, FRCPath, Samir Agrawal
Journal: Blood
Blood (2011) 118 (21): 2832.
https://doi.org/10.1182/blood.V118.21.2832.2832
Published: 2011
Journal Articles

Inter-Laboratory Assessment of Minimal Residual Disease In Chronic Lymphocytic Leukemia – Evaluation of the Novel CD160FCA Assay

Timothy Farren, BSc(HONS), MIBMS, Fengting Liu, MD, PhD, Claire Stephens, MSc, Marion Macey, PhD, FRCPath, Michael Jenner, MD, PhD, FRCPath, Archie Prentice, MB, FRCP, FRCPath, Amit Nathwani, MBChB, FRCP, FRCPath, Samir Agrawal, MD, PhD, FRCPath
Journal: Blood
Blood (2010) 116 (21): 2723.
https://doi.org/10.1182/blood.V116.21.2723.2723
Published: 2010
Journal Articles

CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies.

Timothy W Farren, BSc(HONS), MIBMS, Feng-Ting Liu, MB, PhD, Claire Stephens, MSc, Dimitris Tsitsikas, MBBS, MRCP, Marion G Macey, PhD, FRCPath, Michael Jenner, MD, PhD, John G. Gribben, MD, DSc, Samir G Agrawal, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4382.
https://doi.org/10.1182/blood.V114.22.4382.4382
Published: 2009